2411. Expanded Susceptibility and Resistance Mechanism Testing Among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

2411. Expanded Susceptibility and Resistance Mechanism Testing Among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017

Filetype[PDF-406.76 KB]


Details Supporting Files You May Also Like

Details:

  • Alternative Title:
    Open Forum Infect Dis
  • Personal Author:
  • Description:
    Background

    In Connecticut (CT), submission of clinical carbapenem-resistant Enterobacteriaceae (CRE, resistant to ≥1 carbapenem) isolates to the state public health laboratory (SPHL) was mandated in 2017 for expanded susceptibility and carbapenemase testing. To guide empiric treatment, we created a statewide CRE antibiogram and explored the role of carbapenemase production.

    Methods

    Susceptibility testing was conducted by broth microdilution and disk diffusion and interpreted using Clinical and Laboratory Standards Institute (CLSI) breakpoints, if available. Carbapenemase-producing CRE (CP-CRE) were identified using the modified carbapenem inactivation method (mCIM). Multiplex real-time polymerase chain reaction testing was used to identify genes for common carbapenemases.

    Results

    Of 198 CRE isolates received by the SPHL in 2017, 166 were confirmed as CRE. After patient deduplication, 147 records remained (46.9% Enterobacter, 35.4% Klebsiella, 14.3% Escherichia coli, and 3.4% other). Most were susceptible to ceftazidime/avibactam (CAZ-AVI) (range: 90–100%) and colistin (range 94–100%). Forty-six (31%) were CP-CRE (39 blaKPC, 4 blaNDM, 2 blaOXA-48-like, and 1 gene unknown). Non-CP-CRE were more frequently susceptible (P
    Conclusion

    CP-CRE have demonstrated significant resistance to noncarbapenem antibiotic classes. Most CRE isolates were susceptible to CAZ-AVI and colistin. The predominant carbapenemase gene is blaKPC. This statewide antibiogram can guide empiric prescribing and formulary selection for CRE treatment.

    Disclosures

    All authors: No reported disclosures.

  • Subjects:
  • Source:
    Open Forum Infect Dis. 2018; 5(Suppl 1):S721
  • Pubmed Central ID:
    PMC6253689
  • Document Type:
    Journal Article
  • Volume:
    5
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

You May Also Like

Checkout today's featured content at stacks.cdc.gov